Sebela Pharmaceuticals

“Since inception in 2013, Sebela has been very acquisitive, driving substantial growth while successfully navigating the many related challenges of business integrations, building a cohesive executive team, determining strategic priorities, and executing equity and debt financings. DFW has stood by us shoulder to shoulder every step of the way, always supportive, insightful, solution-focused; bringing their obvious and vast experience to bear enabling us to deliver significant growth and high returns.”

-Alan Cooke, CEO

DFW teamed with Operating Partners Bala Venkataraman and Dr. Virinder Nohria to back two former executives of Alaven Pharmaceutical, a former DFW portfolio company, in a targeted acquisition search to establish a new specialty pharmaceutical platform.   After acquiring an initial product portfolio, DFW assisted the company in building a deep management team and global infrastructure spanning commercial, supply chain, quality, and regulatory capabilities. Through continued proactive business development and M&A, Sebela created a diverse portfolio of branded, marketed products across its three core therapeutic areas of gastroenterology, women’s health and dermatology, supplementing its commercial products with a deep pipeline of long-term growth assets.

Since inception, DFW has supported Sebela’s growth to approximately $250 million in sales and over 300 employees.